The company is not offering or selling any shares under this prospectus, and will not receive any of the proceeds from the sale of the shares by the selling stockholders pursuant to this prospectus.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics Appoints Steven Romano to Board
- Dianthus price target lowered to $36 from $38 at Wedbush
- Dianthus reports Q2 EPS (51c), consensus (55c)